We want to make you aware of some upcoming coverage changes related to the monoclonal antibody medication Remicade (infliximab) and its biosimilars. Effective Jan. 1, 2026 for Harvard Pilgrim Health Care Commercial, Tufts Health Plan Commercial, and Tufts Health Direct members, Avsola and Inflectra will be the preferred infliximab products. Remicade and unbranded Infliximab (HCPCS code J1745) will become a non-preferred products.

Patients currently utilizing Remicade or unbranded Infliximab will not need a new prior authorization request for Avsola or Inflectra in order to transition to one of these two preferred products. Our Medical Benefit Drug MNG for Targeted Immunomodulators Skilled Administration, which you can find here, is being updated to reflect these changes.